OTC · INTP
Integrated Pharmaceuticals, Inc.
$0.00$0.00 (0.0%)
Integrated Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
Loading market information…
OTC · EPRSQ · USD
Stock price, earnings
Quote as of Nov 1, 2023, 04:34 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow EPIRUS Biopharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions. The company's developmental portfolio also encompassed several other biosimilar candidates: BOW050, a biosimilar version of Humira (adalimumab), targeting inflammatory diseases such as rheumatoid arthritis, various adult and pediatric forms of arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis. BOW070, mimicking Actemra (tocilizumab), aimed at rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. BOW080, a biosimilar to Soliris, designed to address ultra-rare blood disorders like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. BOW100, a biosimilar of SIMPONI, for inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. EPIRUS had established strategic alliances, including a licensing arrangement with Sun Pharmaceutical Industries Ltd., a joint licensing and collaboration pact with Livzon Mabpharm Inc., and a collaborative venture with Polpharma S.A. Founded in 2011, the firm maintained its corporate base in Boston, Massachusetts. However, on July 25, 2016, Epirus Biopharmaceuticals, Inc. initiated Chapter 7 liquidation proceedings by submitting a voluntary petition with the US Bankruptcy Court for the District of Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:09 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 13, 2014 | Mar 13, 2014 | -$2.90-107.14% vs estimate | $0.00 |
|---|
KEEP COMPARING
$0.00$0.00 (0.0%)
Integrated Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00-$0.00 (-50.0%)
The Greenrose Holding Company Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
MEDirect Latino, Inc.: Healthcare · Medical - Distribution.
$0.00$0.00 (0.0%)
Xcorporeal, Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
RxElite, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (-90.0%)
Global WholeHealth Partners Corporation: Healthcare · Medical - Diagnostics & Research.
$0.00-$0.00 (0.0%)
Molecular Templates, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$0.00+$0.00 (0.0%)
Arch Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
